Evidence map›Paper›PMID 27354010›Full record

ArticlePediatric blood & cancer2016

Severe, persistent, and fatal T-cell immunodeficiency following therapy for infantile leukemia.

Ashley V Geerlinks, Thomas Issekutz, Justin T Wahlstrom, Kathleen E Sullivan, Morton J Cowan, Christopher C Dvorak, Conrad V Fernandez

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Severe immunodeficiency associated with acute lymphoblastic leukemia and its treatment.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Ashley V GeerlinksDepartment of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, NS, Canada. Ashley.geerlinks@iwk.nshealth.ca.
Thomas IssekutzDepartment of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, NS, Canada.
Justin T WahlstromDepartment of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA.
Kathleen E SullivanDepartment of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, CA.
Morton J CowanDepartment of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA.
Christopher C DvorakDepartment of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA.
Conrad V FernandezDepartment of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, NS, Canada.
Dalhousie University · CAUCSF Benioff Children's Hospital · USChildren's Hospital of Philadelphia · USIzaak Walton Killam Health Centre · CAUniversity of California, San Francisco · US

Funding

Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
NCI NIH HHS T32 CA128583
6 · The paper itself

Abstract

We describe five cases of children who completed chemotherapy for infantile acute lymphoblastic leukemia (ALL) and soon after were diagnosed with severe T-cell, non-HIV immunodeficiency, with varying B-cell and NK-cell depletion. There was near absence of CD3(+) , CD4(+) , and CD8(+) cells. All patients developed multiple, primarily opportunistic infections. Unfortunately, four patients died, although one was successfully treated by hematopoietic stem cell transplantation. These immunodeficiencies appeared to be secondary to intensive infant ALL chemotherapy. Our report highlights the importance of the early consideration of this life-threatening immune complication in patients who received chemotherapy for infantile ALL.

Indexed as

ChildChild, PreschoolFatal OutcomeHematopoietic Stem Cell TransplantationHumansImmunologic Deficiency SyndromesPrecursor Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesALLdeathimmunocompromised hostimmunodeficiencyinfant leukemiamolecular diagnosis and therapy

Identifiers

PMID27354010
PMCPMC7168093
OpenAlexW2466370195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.